TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24156746

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 70
Study: 21519043

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (placebo-controlled trial)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: ISAS
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Effect sizes of 0.48 detected in several trials
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: ISAS scores
Number of subjects: 315
Study: 18326619

Group type: EXPERIMENTAL
Intervention: Novel galactooligosaccharide (0, 3.6, or 7 g/d)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Novel galactooligosaccharide (7 g/d)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Novel galactooligosaccharide (0, 3.6, and 7 g/d)
Number of subjects: 59
Study: 16552819

Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no IFN-alpha treatment)
Number of subjects: 38
Study: 12666702

Group type: EXPERIMENTAL
Intervention: Scaling and root planing with hand instruments and application of EMD
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Scaling with an ultrasonic instrument and application of EMD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Scaling with an ultrasonic instrument alone
Number of subjects: 16
Study: 11009277

Group type: EXPERIMENTAL
Intervention: Probucol administered beginning 4 weeks before PTCA
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no probucol)
Number of subjects: 101
Study: 8775577

Group type: EXPERIMENTAL
Intervention: Nasal lavages (NAL) performed on amateur runners after the marathon race.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nasal lavages (NAL) performed on healthy sedentary subjects (control group).
Number of subjects: 60
Study: 1594169

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol and Placebo
Number of subjects: 12
Study: 3882181

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 5 mg twice daily
Number of subjects: 0
Study: 30367958

Group type: EXPERIMENTAL
Intervention: Ketogenic formula (Ketonformula®) containing 20g of MCTs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isocaloric placebo formula without MCTs
Number of subjects: 20
Study: 28475703

Group type: EXPERIMENTAL
Intervention: Cibinetide 1 mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cibinetide 4 mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cibinetide 8 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 25512031

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg) added to bupivacaine (0.25% solution with adrenaline)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bupivacaine (0.25% solution with adrenaline) alone
Number of subjects: 48
Study: 23774272

Group type: EXPERIMENTAL
Intervention: Increased dairy food intake
Number of subjects: 180

Group type: COMPARATOR
Intervention: No change in dairy food intake
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Decreased dairy food intake
Number of subjects: 180
Study: 22585373

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate oral disintegrating tablets (specific formulation details: magnesium stearate as lubricant, hydrophobic Aerosil R972 as glidant, low urea content, mannitol/microcrystalline cellulose ratio 2:1, and 9% Plasdone XL100 as superdisintegrant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical blend of miconazole nitrate
Number of subjects: 0
Study: 19425222

Group type: EXPERIMENTAL
Intervention: continued cART (n=48)
Number of subjects: 145

Group type: COMPARATOR
Intervention: interrupted cART (n=97)
Number of subjects: 145
Study: 17689635

Group type: EXPERIMENTAL
Intervention: Rise in systolic blood pressure over 30 mm Hg
Number of subjects: 5167

Group type: EXPERIMENTAL
Intervention: Rise in diastolic blood pressure over 15 mm Hg
Number of subjects: 5167

Group type: EXPERIMENTAL
Intervention: Women experiencing early preterm birth
Number of subjects: 5167

Group type: EXPERIMENTAL
Intervention: Women experiencing late preterm birth
Number of subjects: 5167
Study: 15066949

Group type: COMPARATOR
Intervention: Dietary modification only
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Diet plus a supervised structured exercise program
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continuing exercise program
Number of subjects: 82
Study: 11844850

Group type: EXPERIMENTAL
Intervention: Vaccine with S. aureus type 5 and 8 capsular polysaccharides conjugated to nontoxic recombinant Pseudomonas aeruginosa exotoxin A
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 1804
Study: 10549094

Group type: EXPERIMENTAL
Intervention: i.v. application of FXIII concentrate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8527465

Group type: EXPERIMENTAL
Intervention: Motor training programs (active and mental)
Number of subjects: 96
Study: 2155747

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 14

Group type: COMPARATOR
Intervention: Trimetaphan camsylate
Number of subjects: 14
Study: 6966069

Group type: EXPERIMENTAL
Intervention: Splenectomized patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-splenectomized patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study: 6136100

Group type: EXPERIMENTAL
Intervention: Brotizolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31352621

Group type: EXPERIMENTAL
Intervention: Endometrial receptivity array (ERA) test in Euploid‐ET
Number of subjects: 24

Group type: COMPARATOR
Intervention: Euploid‐ET control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endometrial receptivity array (ERA) test in Donor‐ET
Number of subjects: 24

Group type: COMPARATOR
Intervention: Donor‐ET control group
Number of subjects: 24
Study: 30036871

Group type: EXPERIMENTAL
Intervention: Combined exercise and cognitive training for 6 consecutive weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 26781281

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (1.6 g per day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25484023

Group type: EXPERIMENTAL
Intervention: Maternal n-3 PUFA supplementation during pregnancy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no n-3 PUFA supplementation)
Number of subjects: 70
Study: 22658255

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 27
Study: 20384650

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg bid
Number of subjects: 504

Group type: COMPARATOR
Intervention: Amiodarone 600 mg qd for 28 days then 200 mg qd
Number of subjects: 504
Study: 18715950

Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium (MGd) at doses of 1.7 to 9.2 mg/kg daily prior to radiation therapy for 6 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium (MGd) administered as a 5-min intravenous bolus 2-5 h prior to standard radiation therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Involved field radiation therapy administered to 54 Gy in 30 once-daily fractions
Number of subjects: 44
Study: 14975200

Group type: EXPERIMENTAL
Intervention: HRT plus fluoxetine
Number of subjects: 123

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 123
Study: 11700394

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of rhAPC (12, 18, 24, or 30 microg/kg/hr) for 48 or 96 hrs
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo for 48 or 96 hrs
Number of subjects: 131
Study: 9210983

Group type: EXPERIMENTAL
Intervention: Coffee with milk
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tea with milk
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (black coffee or black tea without milk)
Number of subjects: 12
Study: 7961049

Group type: EXPERIMENTAL
Intervention: Tangential dipole activity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radial dipole activity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Retesting after three weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Age correlation
Number of subjects: 40
Study: 3300294

Group type: EXPERIMENTAL
Intervention: 50 mL of 100% alcohol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acute moderate alcohol intake
Number of subjects: 8
Study: 29366377

Group type: EXPERIMENTAL
Intervention: Narrow-pulse NMES
Number of subjects: 27
Study: 26409172

Group type: EXPERIMENTAL
Intervention: CIM331
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24750301

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study: 22901887

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three times a week for 6 months
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 141
Study: 20739893

Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway (RLMA)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 134
Study: 17394477

Group type: EXPERIMENTAL
Intervention: Individualized face-to-face counseling session followed by phone contacts every 3 months.
Number of subjects: 632

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 632
Study: 15680528

Group type: EXPERIMENTAL
Intervention: Hypothermic cohort
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normothermic cohort
Number of subjects: 61
Study: 12093059

Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 9840513

Group type: COMPARATOR
Intervention: Cold laryngeal mirror stimulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cold water swallowing
Number of subjects: 14
Study: 8023546

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Havrix) stored at 37 degrees C for 1 week
Number of subjects: 2

Group type: COMPARATOR
Intervention: Inactivated hepatitis A vaccine (Havrix) stored at 2-8 degrees C
Number of subjects: 2
Study: 2657055

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily
Number of subjects: 165

Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 165
Study: 31928364

Group type: EXPERIMENTAL
Intervention: Broad-spectrum micronutrient formula
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vitamin B6 (80 mg/day)
Number of subjects: 78
Study: 30515840

Group type: EXPERIMENTAL
Intervention: Distraction from provoking cues
Number of subjects: 119

Group type: COMPARATOR
Intervention: No-distraction control condition
Number of subjects: 119
Study: 30057745

Group type: EXPERIMENTAL
Intervention: GM604
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GM604 (compassionate treatment)
Number of subjects: 12
Study: 26531865

Group type: EXPERIMENTAL
Intervention: Suboptimal SCIT (30,000 standardized quality units) plus anti-IL-4 (VAK694)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Suboptimal SCIT (30,000 standardized quality units) plus placebo antibody
Number of subjects: 37

Group type: COMPARATOR
Intervention: Double placebo (placebo SCIT and placebo antibody)
Number of subjects: 37
Study: 24978623

Group type: EXPERIMENTAL
Intervention: Internet parenting education and support intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Online education healthy lifestyle course
Number of subjects: 60
Study: 23022391

Group type: EXPERIMENTAL
Intervention: 20 mg Ze 440
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 30 mg Ze 440
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 8 mg Ze 440
Number of subjects: 162
Study: 19933962

Group type: EXPERIMENTAL
Intervention: Intervention group (physician and pharmacist collaboration)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 402
Study: 17514629

Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone (MP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral prednisolone (P)
Number of subjects: 19
Study: 15302290

Group type: EXPERIMENTAL
Intervention: Optimal surgical treatment plus adhesion barrier (SprayGel)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Optimal surgical treatment alone
Number of subjects: 66
Study: 11251012

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg (20 mg maximum)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 32
Study: 10203559

Group type: EXPERIMENTAL
Intervention: Enteral nutrition via nasogastric tube
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 32
Study: 8580980

Group type: EXPERIMENTAL
Intervention: Moxisylyte 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moxisylyte 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moxisylyte 30 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2090770

Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha‐2b (rIFN alpha‐2b) 5 MU/m2 thrice weekly for 16 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 772817

Group type: EXPERIMENTAL
Intervention: Azathioprine (50 to 175 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Azathioprine (after placebo)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 16
Study: 31166260

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Number of subjects: 74
Study: 28459181

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Advanced Moist Wound Therapy (Control)
Number of subjects: 40
Study: 26683057

Group type: EXPERIMENTAL
Intervention: Low-dose-induction oral immunotherapy (OIT) with 3 ml of milk, administered daily after a 5-day hospital build-up period.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (complete elimination of milk intake).
Number of subjects: 37
Study: 23660209

Group type: EXPERIMENTAL
Intervention: Modified transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Posterolateral fusion (PLF)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Modified TLIF
Number of subjects: 28

Group type: COMPARATOR
Intervention: PLF
Number of subjects: 28
Study: 21834711

Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 μm aluminum oxide particles at a pressure of 87 psi
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (excavator)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 40% polyacrylic acid
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mixture of flour pumice and water
Number of subjects: 33
Study: 19192230

Group type: EXPERIMENTAL
Intervention: ELTGOL plus medical therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 59
Study: 17364305

Group type: EXPERIMENTAL
Intervention: High intensity, high‐frequency TENS (HI TENS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low intensity, high‐frequency TENS (LI TENS)
Number of subjects: 21
Study: 15488162

Group type: EXPERIMENTAL
Intervention: Washing of the CVP using normal saline solution before each closure and every 6 hours
Number of subjects: 83

Group type: COMPARATOR
Intervention: Closure of the CVP using an obturator after the suspension of the infused therapy
Number of subjects: 83
Study: 11201509

Group type: EXPERIMENTAL
Intervention: Estrogen (Premarin 0.625 mg) and oral micronized progesterone (Prometrium 200 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Estrogen (Premarin 0.625 mg) and medroxyprogesterone acetate (Provera 5 mg)
Number of subjects: 21
Study: 9571553

Group type: EXPERIMENTAL
Intervention: Final smoothing after PRK or LASIK
Number of subjects: 147

Group type: COMPARATOR
Intervention: Patched immediately after PRK or LASIK
Number of subjects: 147
Study: 1637279

Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone metasulphobenzoate for 3 months
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 113
Study: 6711431

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 30457557

Group type: EXPERIMENTAL
Intervention: Chitosan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgicel
Number of subjects: 50
Study: 29582360

Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™
Number of subjects: 165

Group type: COMPARATOR
Intervention: LMA® Supreme™
Number of subjects: 165
Study: 27210823

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 50
Study: 23827130

Group type: EXPERIMENTAL
Intervention: Ornithine ingestion (400 mg/d) for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21073640

Group type: EXPERIMENTAL
Intervention: Make A Difference about Art programme (art therapy intervention)
Number of subjects: 297
Study: 19183113

Group type: EXPERIMENTAL
Intervention: Advanced monitoring (AM) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional monitoring (CM) group
Number of subjects: 40
Study: 17510712

Group type: EXPERIMENTAL
Intervention: AdheSE (Ivoclar Vivadent)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus-Self-Etch (Kerr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tyrian SPE (Bisco)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adper Prompt Self-Etch (3M Espe)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: One-Up Bond F (Tokuyama)
Number of subjects: 10
Study: 15085873

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine solution applied into the inner space of 23 fixtures (test group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline applied into the inner space of 23 fixtures (control group)
Number of subjects: 12
Study: 11905780

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy for advanced laryngeal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy given concomitantly with radiotherapy
Number of subjects: 0
Study: 9737644

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025-0.4 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin (higher doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin (long-term administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerivastatin
Number of subjects: 0
Study: 7536025

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy consisting of carboplatin 1600 mg m-2, thiotepa 480 mg m-2 and cyclophosphamide 6 g m-2 (CTC) followed by PBSC transplantation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: G-CSF (Filgrastim) 300 microgram s.c. daily
Number of subjects: 29
Study: 2665058

Group type: EXPERIMENTAL
Intervention: Insulin (7.5 U fast-acting insulin/kg b.w. as a bolus followed by continuous infusion of 15 U/kg b.w. for 1 hour)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no insulin treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 903408

Group type: EXPERIMENTAL
Intervention: Monterey program for the syntactic structure 'is interrogative' plus an extended transfer program
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Monterey 'is interrogative' program alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control activity (articulation training)
Number of subjects: 9
Study: 31076561

Group type: EXPERIMENTAL
Intervention: Metformin combined with neoadjuvant chemotherapy and trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control regimen without metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin-containing arm
Number of subjects: 0
Study: 28613947

Group type: EXPERIMENTAL
Intervention: Continuous exercise (CON)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Circuit-based exercise (CIRC)
Number of subjects: 12
Study: 24299007

Group type: EXPERIMENTAL
Intervention: PEG membrane
Number of subjects: 37

Group type: COMPARATOR
Intervention: Collagen membrane (control)
Number of subjects: 37
Study: 23324914

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical valve replacement
Number of subjects: 0
Study: 21981870

Group type: EXPERIMENTAL
Intervention: Hand acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laser-needle acupuncture
Number of subjects: 20
Study: 19524144

Group type: EXPERIMENTAL
Intervention: Hartslag Limburg intervention
Number of subjects: 3114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3114
Study: 17047539

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (15 mug)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 60
Study: 12774010

Group type: EXPERIMENTAL
Intervention: ACE (epirubicin, cyclophosphamide, and etoposide)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PACE (prednisolone + ACE)
Number of subjects: 50